Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $87.00 Consensus PT from Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $87.00.

A number of research analysts have recently commented on ESTA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Mizuho raised their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen raised shares of Establishment Labs from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup increased their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Finally, Canaccord Genuity Group raised their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th.

Establishment Labs Stock Down 1.4%

ESTA stock opened at $70.38 on Thursday. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.10. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31. The company has a 50-day moving average of $70.89 and a two-hundred day moving average of $59.68. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -40.45 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.19) earnings per share. As a group, equities research analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds have recently made changes to their positions in ESTA. Simplify Asset Management Inc. acquired a new stake in shares of Establishment Labs during the 3rd quarter worth approximately $1,555,000. Tejara Capital Ltd raised its stake in shares of Establishment Labs by 31.2% in the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after purchasing an additional 24,386 shares in the last quarter. Woodson Capital Management LP lifted its position in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after purchasing an additional 255,000 shares during the period. Affinity Asset Advisors LLC lifted its position in Establishment Labs by 19.6% in the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock worth $14,302,000 after purchasing an additional 54,863 shares during the period. Finally, Hood River Capital Management LLC boosted its stake in Establishment Labs by 138.2% during the second quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock worth $2,269,000 after buying an additional 30,825 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.